Bank of New York Mellon Corp Has $10.16 Million Stock Position in Health Catalyst, Inc. (NASDAQ:HCAT)

Bank of New York Mellon Corp cut its position in shares of Health Catalyst, Inc. (NASDAQ:HCAT) by 37.6% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 1,437,006 shares of the company’s stock after selling 865,743 shares during the quarter. Bank of New York Mellon Corp owned 2.36% of Health Catalyst worth $10,160,000 at the end of the most recent quarter.

Other hedge funds also recently made changes to their positions in the company. Legato Capital Management LLC lifted its position in shares of Health Catalyst by 3.7% during the fourth quarter. Legato Capital Management LLC now owns 87,992 shares of the company’s stock worth $622,000 after purchasing an additional 3,171 shares in the last quarter. Quest Partners LLC acquired a new stake in shares of Health Catalyst during the third quarter worth $34,000. SG Americas Securities LLC grew its holdings in shares of Health Catalyst by 21.7% during the fourth quarter. SG Americas Securities LLC now owns 27,382 shares of the company’s stock worth $194,000 after buying an additional 4,874 shares in the last quarter. Franklin Resources Inc. boosted its holdings in Health Catalyst by 5.8% during the third quarter. Franklin Resources Inc. now owns 104,141 shares of the company’s stock worth $857,000 after purchasing an additional 5,687 shares during the last quarter. Finally, Inspire Investing LLC increased its position in shares of Health Catalyst by 14.2% in the fourth quarter. Inspire Investing LLC now owns 56,379 shares of the company’s stock valued at $399,000 after acquiring an additional 7,019 shares during the last quarter. Institutional investors and hedge funds own 85.00% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts have recently issued reports on the stock. Citigroup dropped their target price on shares of Health Catalyst from $10.50 to $10.00 and set a “buy” rating on the stock in a report on Friday, January 10th. KeyCorp raised Health Catalyst from a “sector weight” rating to an “overweight” rating and set a $9.00 price objective on the stock in a research note on Wednesday, January 8th. Piper Sandler dropped their target price on Health Catalyst from $12.00 to $8.00 and set an “overweight” rating for the company in a research report on Tuesday, February 11th. Royal Bank of Canada dropped their price target on shares of Health Catalyst from $7.00 to $6.00 and set a “sector perform” rating on the stock in a research report on Thursday, February 27th. Finally, Canaccord Genuity Group dropped their target price on shares of Health Catalyst from $11.00 to $10.00 and set a “buy” rating on the stock in a research report on Tuesday, January 21st. Three investment analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $9.27.

Health Catalyst Stock Down 7.2 %

HCAT opened at $4.11 on Friday. Health Catalyst, Inc. has a fifty-two week low of $3.76 and a fifty-two week high of $9.24. The firm has a market capitalization of $288.57 million, a P/E ratio of -3.04 and a beta of 1.41. The company’s 50-day moving average is $5.50 and its 200 day moving average is $7.07. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.41 and a quick ratio of 1.41.

Insider Buying and Selling at Health Catalyst

In other news, COO Daniel Lesueur sold 16,902 shares of the company’s stock in a transaction that occurred on Wednesday, March 5th. The stock was sold at an average price of $4.52, for a total value of $76,397.04. Following the completion of the transaction, the chief operating officer now directly owns 216,250 shares of the company’s stock, valued at $977,450. This represents a 7.25 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, General Counsel Benjamin Landry sold 13,827 shares of Health Catalyst stock in a transaction on Thursday, March 6th. The stock was sold at an average price of $4.55, for a total value of $62,912.85. Following the sale, the general counsel now owns 160,437 shares in the company, valued at $729,988.35. This trade represents a 7.93 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 71,972 shares of company stock worth $412,930. Insiders own 2.50% of the company’s stock.

About Health Catalyst

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.